In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
491 News Items found
Dr. Bob Li
First Drug Targeting HER2-Mutant Non-Small Cell Lung Cancer Approved by FDA

The FDA has approved the drug trastuzumab deruxtecan for the treatment of advanced non-small cell lung cancer driven by mutant HER2. An MSK-led study published in September 2021 contributed to the drug's approval.
Through-the-microscope view of a tissue sample
MSK Research Highlights, July 17, 2023

New MSK research identified a way to reduce toxicity in CAR T cell therapy; discovered a division of labor in DNA repair that suggests a possible therapeutic strategy for certain cancers; developed a new method to enable imaging of two PET tracers simultaneously; found biomarkers that could help predict outcomes in HER2-positive metastatic esophagogastric cancer; and made progress toward improving options for patients with early-stage, potentially indolent cancers.
wedding-day photo of bride and groom embracing outside under a dramatic evening sky
A Love Story and a Legacy at MSK

Tom Scalera and Brett Ravage found a second chance at love through the MSK community after losing their spouses to cancer in 2019. Together, they have raised more than $10 million for cancer research.
Microscopic image of cancer cells and C. elegans cells undergoing entosis.
In the Lab
A Death Wish That Allows Worms to Thrive — and What It Tells Us About Cancer Biology

Researchers discover that a curious type of cell death plays a role in normal development.
MSK computational biologist Sohrab Shah
Scientists Obtain Real-Time Look at How Cancers Evolve

With the help of machine learning, computational biologists are learning to predict how cancers will evolve.
Samuel Danishefsky
Memorial Sloan Kettering Enters Agreement to Develop New Cancer Drug

As part of a commitment to seek new and better treatments for cancer patients, Memorial Sloan Kettering Cancer Center and Bristol-Myers Squibb are collaborating to bring a potential new cancer drug called iso-fludelone, or KOS-1803, into clinical trials.
Ingo Mellinghoff, Chair of the Department of Neurology at Memorial Sloan Kettering
Brain Trust: 8 Questions with Ingo Mellinghoff

Ingo Mellinghoff is optimistic about the future of brain cancer treatments as the new Chair of MSK’s Department of Neurology.
MSK researcher in a lab
MSK Research Highlights, August 24, 2023

New MSK research suggests a method for revealing DNA repair “scars” could help make treatment decisions in BRCA1- and BRCA2-deficient cancers; modified a bacteria-made compound to target mutant KRAS-driven cancers; and shed new light on brain metastasis in non-small cell lung cancer.
MSK scientists Andrew Kung and Elli Papaemmanuil
New Type of Genetic Testing Aims To Benefit Children and Young Adults With Cancer

By sequencing the entire genome of a tumor, the experimental test will go beyond standard testing for common cancers in adults.
Jeffrey Drebin
The Crucial Need for Cancer Treatment and Screening During COVID-19

In a recent interview, MSK's Dr. Jeffrey Drebin addressed why it’s important for people to keep up with their routine screenings and not put off cancer treatment or surgery.